MAP2K7 and non-small cell lung carcinoma: Therefore, therapeutic strategies to block either the MEK or PI3K pathway are not sufficient to inhibit the growth of NSCLC cells, providing the rationale for combining therapeutic agents that could simultaneously block both pathways [19].